Molecular Formula | C17H11ClF3N5O3 |
Molar Mass | 425.75 |
Melting Point | >278°C (dec.) |
Solubility | DMSO: ≥ 30 mg/mL |
Appearance | Solid |
Color | White to Off-White |
Storage Condition | -20°C Freezer |
Use | Doravirine (MK-1439) is a highly specific HIV-1 non-nucleoside reverse transcriptase inhibitor. The IC50 values for wild type and K103N and Y181C reverse transcriptase mutants are 4.5 nM,5.5 nM and 6.1 nM, respectively. |
In vitro study | MK-1439 have an IC50 greater than 100 μm for DNA polymerases α, ß, and γ in the cell. In the 110 protein target (including enzymes, transporters, ion channels and receptors) screening, MK-1439 IC50 values for most targets are greater than 10 μm, except for 5-HT2β, its IC50 value was MK-1429 to be 2.5 μm in the ligand binding assay. However, in experiments measuring the accumulation of inositol-1-phosphate in cells, no 5-HT2ß activity was detected. In activated CD4 T cells, peripheral blood mononuclear cells, macrophage proliferation of transformed cell lines, the concentration of up to 100 M MK-1439 without cytotoxicity. |
In vivo study | In rats, administered by intravenous injection (1 mg/kg), the MK-1439 has a plasma clearance of 5.4 mL/min/kg and a half-life of 4.4 hours, the volume of distribution was 2.3 L/kg. The oral bioavailability was 57% with 5 mg/kg administered by oral route. In beagle dogs, a plasma clearance of 0.36 mL/min/kg with a half-life of 37 hours was achieved by intravenous injection of 0.5 mg/kg of MK-1439. The oral bioavailability of MK-1439 in Beagle dogs was 52% at 1 mg/kg by oral route. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.349 ml | 11.744 ml | 23.488 ml |
5 mM | 0.47 ml | 2.349 ml | 4.698 ml |
10 mM | 0.235 ml | 1.174 ml | 2.349 ml |
5 mM | 0.047 ml | 0.235 ml | 0.47 ml |